QM · rank #1 · 2026-07-27
LQDA
NASDAQ · $7.67B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +496.72% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +28.2% |
| Profit margin Net profit margin, trailing 12 months. | +7.7% |
| Market cap (USD) Size filter: > $500M required. | $7.67B |
| Anchor (recent) Close on 2026-06-26 | $78.17 |
| Anchor (far) Close on 2025-06-27 | $13.10 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Liquidia Technologies is a commercial-stage pulmonary hypertension company generating nearly all revenue from YUTREPIA, a dry-powder inhaled treprostinil that ramped to $132.9M in Q1 2026 revenue and delivered its third consecutive profitable quarter.
Rationale
The quality_momentum signal is directly reinforced by LQDA's explosive revenue inflection (Q1 revenue up ~43x YoY), positive and expanding ROE of 28%, and 44% sequential YUTREPIA sales growth — exactly the kind of fundamental earnings acceleration that sustains price momentum rather than mere sentiment rotation.
Material risks
- 1Single-product concentration in YUTREPIA means any safety signal, manufacturing disruption, or adverse payer/formulary decision collapses both revenue and the profitability thesis simultaneously with no offsetting asset.
- 2Larger incumbents (United Therapeutics with Tyvaso) have entrenched prescriber relationships and IP resources to contest LQDA's market share gains, and any adverse patent ruling or label restriction could abruptly cap YUTREPIA's commercial runway.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.